Philip Ferneau
QuietNamed in filings at BorealisOn the current fund
- Board seats filed
- 8
Named in filings at BorealisOn the current fund
all filings on record
last 24 months
from a verified or cited source
| Ovation.io | Biotech & pharma | September 2024 | Madrona Venture Group |
| Amagma | Biotech & pharma | May 2022 | Atlas Venture, Polaris Partners |
| Ankyra Therapeutics | Biotech & pharma | August 2021 | Mithril, Polaris Partners |
| Compass Therapeutics | Biotech & pharma | June 2020 | 270 Healthcare Growth, Caduceus Capital, Orbimed Asia Partners, Orbimed Genesis |
| Compass Therapeutics | Biotech & pharma | June 2015 | 270 Healthcare Growth, 82vs, Caduceus Capital, GTP AW, Orbimed Asia Partners, Orbimed Genesis |
| Direct Vet Marketing | Enterprise software | March 2015 | Atlas Venture, HLM Strategic Investment, HLM Venture Partners, Insight |
| Avitide | Biotech & pharma | May 2014 | 82vs, GTP AW, Mithril, SV Life Sciences, Virtuoso-mccarran |
| AVEDRO | Medical devices | June 2011 | Abingworth Bioventures, Aperture, Caduceus Capital, Healthquest Partners, Orbimed Asia Partners, Orbimed Genesis, Sofinnova Venture Partners, Vivo Innovation |
The company and date are what the SEC filing shows, not a statement of investment thesis. A partner can sit on a board for reasons that say nothing about what their firm funds today. The sector is not a filing value: it is Lev’s own classification of each company, shown only when we found a specific, checkable source for it; otherwise it reads “Not yet classified.” “Also on the board from” names another tracked firm with a partner on the same board, both with a clean identity match. It is not a claim either firm led or co-led the round, and “None on file” means no other tracked firm’s partner shares this specific board seat, not that no one else invested. Sorted newest first by default; click a column to change it. Something wrong? Tell us.
Classified sectors of companies where filings name Philip Ferneau on the board, based on 8 filed seats with a verified or cited source.